膀胱腫瘍に対するTegafur坐剤の応用

Abstract

1)膀胱腫瘍20例(TaNxMo 8例, T1NxMo 5例, T2NxMo 3例, T3aNxMo 1例, T3bN2Mo 1例, T3bNxMo 1例, T4NxMo 1例)に750 mg Tegafur坐剤1個を連日23～161日(平均47.45日)を投与した.投与総量は17.25～120.75g(平均34.45g)であった.2)斉藤・小山班の固形がん化学療法直接効果判定基準にもとづき効果判定をおこなうと, CR0例(0%), PR5例(25%), MR3例(15%), NC 10例(50%), PD2例(10%)で, Response rate(奏効率)は25.0%であった.3) 20例中6例(30%)になんらかの副作用が認められた.すなわち全身倦怠感4例(20%), 食欲不振3例(15%), 下痢1例(5%), 浮腫1例(5%), 貧血2例(10%), GOT・GPT上昇1例(5%)および血小板減少1例(5%)が認められた.これら副作用も投薬の休止および保存的療法にて消褪した

A Tegafur suppository of 750 mg was administered daily to 20 patients with bladder tumors, whose ages ranged from 43 to 84 years (average age 63.7). Histological study revealed transitional cell papilloma in 6 cases, transitional cell carcinoma in 12 cases, squamous cell carcinoma in 1 case and malignant tumor with extensive necrosis in 1 case. The result of staging and grading was as follows: 8 cases of pTa, 5 cases of pT1, 9 cases of pT2, 1 case of pT3a, 2 cases of pT3b and 1 case of T4; an, 6 cases of G0, 6 cases of G1, 5 cases of G2, 2 cases of G3 and 1 case of unknown grade. According to Saitoh and Koyama's criteria, no cases showed complete response (0%), 5 cases partial response (25%), 3 cases minor response (15%), 10 cases no change (50%) and 2 cases progressive disease, making the total effective rate 25.0%. Some side effects were observed in 6 of the cases (30%): General malaise in 4 cases (20%), loss of appetite in 3 cases (15%), diarrhea in 1 case (5%), edema in 1 case (5%), anemia in 2 cases (10%), an elevation of both GOT and GPT in 1 case (5%) and thrombocytopenia in 1 case (5%). A recovery from these side effects was achieved after discontinuing the use of Tegafur suppositories.